Prognostic Value of Comorbidity for Auto-SCT Eligibility and Outcome in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Bone Marrow Transplantation - United Kingdom
doi 10.1038/bmt.2010.188
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

New England Journal of Medicine
Medicine
2015English

Treatment of Refractory and Relapsed Hodgkin's Lymphoma: Facts and Perspectives

Haematologica
Hematology
2007English

Prognostic Factors in Aggressive Non‐Hodgkin's Lymphomas

Oncologist
Cancer ResearchMedicineOncology
1998English

Prognostic Nomogram Incorporating Inflammatory Cytokines for Overall Survival in Patients With Aggressive Non-Hodgkin's Lymphoma

EBioMedicine
BiochemistryMedicineGeneticsMolecular Biology
2019English

Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome

Biology of Blood and Marrow Transplantation
TransplantationHematology
2013English

Haploidentical Hematopoietic Stem Cell Transplantation Compared With Hla-Matched Stem Cell Transplantation for Refractory or Relapsed Aggressive Non-Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Nivolumab for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

LACE-conditioned Autologous Stem Cell Transplantation for Relapsed or Refractory Hodgkin's Lymphoma: Treatment Outcome and Risk Factor Analysis in 67 Patients From a Single Centre

Bone Marrow Transplantation
TransplantationHematology
2006English

Brentuximab Vedotin for Relapsed or Refractory Hodgkin Lymphoma: Experience in Turkey

Annals of Hematology
MedicineHematology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy